Health care stocks declined late Tuesday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund both down around 0.5%.
The iShares Biotechnology ETF shed.
AMTAGVI is the first and only one-time, individualized T cell therapy to receive U.S. FDA approval for a solid tumor cancer.
PHILADELPHIA, PA. - WuXi Advanced Therapies , a wholly owned subsidiary.
Shares of International Flavors & Fragrances Inc. (NYSE: IFF) fell during Wednesday’s session after the company reported mixed fourth-quarter financial results and reduced its expected quarterly dividend approximately 50% to 40 cents per share.
The FDA has granted accelerated approval to a new type of cellular therapy for use in people who have skin cancer which has spread to other parts of the body.